+49 30 648 35 164 service@chameleon-pharma.com

Novo Nordisk opens a new insulin production plant in Russia

Novo Nordisk is a well-known international pharmaceutical corporation, specializing in insulin products. It has been one of the leaders for diabetes treatment products for over ninety years. The company has offices in about seventy-five countries and has approximately 41,500 employees. It has production facilities in Denmark, France, Brazil, China and the U.S. and many other places.
After two years of construction, it has recently opened a production plant in Kaluga, Russia.

It is estimated that there are about ten million people suffering from diabetes in Russia. The plant is thus very important for Russian citizens who need insulin products several times a day.
The new plant will include facilities for manufacturing insulin solutions, filling and packaging. The plant consists of multiple high-tech production tools and corresponds to GMP standards.
The plant was built according to the latest ecological standards. This is the first production facility in Russia built in this way. The facility will have safe and eco-friendly levels of CO2 emission, water consumption and energy consumption. Moreover, the plant provides employment for more than 150 people.

Featured image: “The gift of Life” by Melissa Johnson

Contact us

1 + 7 =

Related Posts

Meet CPC at expopharm Munich 2026: Explore Pharmacy and

Meet CPC at expopharm Munich 2026: Explore Pharmacy and

Meet Chameleon Pharma Consulting CEO Reiner Christensen at expopharm Munich from 15–17 September 2026. Arrange an individual meeting to discuss pharmacy trends, international market entry, partner identification, and consumer healthcare opportunities.

Mexico’s New Fast-Track Drug & Medical Device Registration

Mexico’s New Fast-Track Drug & Medical Device Registration

Mexico is reshaping its COFEPRIS registration system with a new abbreviated Reliance pathway for eligible drugs and Medical Devices. With review targets of 45 business days for medicines and CPC Fast-Track registration strategies targeting approximately 10–15 months, the new framework creates important opportunities for faster market entry.

Meet Chameleon Pharma Consulting at CPHI Milan 2026

Meet Chameleon Pharma Consulting at CPHI Milan 2026

Meet Chameleon Pharma Consulting CEO Reiner Christensen at CPHI Milan from 6–8 October 2026. Schedule a meeting to discuss international market entry, licensing, partner identification, and growth opportunities for your pharma or consumer healthcare business.

Our services

i

International Company Partner Identification

Licensing and
M&A

Product Potential & Country Analysis

International Business & Market Entry

U

Pharma Regulatory & Registration

Pharma Executive
Search

International Strategy & Analysis

Market Reports and Analysis